Recruiting NCT06637332
Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Daptomycin for Injection, Vancomycin (IV).
- Who it may be relevant to
- Registry conditions: Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia, S. Aureus Bacteremia, S. Aureus Bloodstream Infection. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Australia, Canada
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
DAPTO-SNAP: Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
Overview
This is an open label randomized controlled trial for patients with methicillin resistant S. aureus (MRSA) bloodstream infection which will directly compare the two most commonly used therapies, vancomycin and daptomycin. This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)
Interventions
- Drug Daptomycin for Injection
Daptomycin given by injection at a dose determined by the treating team but not to be less than 6mg/kg - Drug Vancomycin (IV)
Vancomycin by injection to be given at a dose selected by the treating team to achieve a desired trough level or AUC-based target, as determined by local standards of care
Primary outcome measures
- Desirability of Outcome Ranking (DOOR) [Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)]
Secondary outcome measures (6)
- Clinical failure [Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)]
- Serious Adverse Event or Adverse Event Leading to Discontinuation [Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)]
- All cause mortality [Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)]
- Infectious Complications [Time frame: Day 90 post enrollment in the S. aureus Network Adaptive Platform Trial (NCT05137119)]
- Drug Induced Myostitis [Time frame: Occurring while on therapy up to day 42 from enrollment in SNAP (NCT05137119)]
- Eosinophilic pneumonia [Time frame: Occurring while on therapy up to day 42 from enrollment in SNAP (NCT05137119)]
Eligibility criteria
The participant must meet all inclusion and exclusion criteria for the SNAP Platform (NCT05137119) and also the following inclusion and exclusion criteria:
Inclusion criteria
- Methicillin-resistant S. aureus bacteremia
Exclusion criteria
- Severe allergy or non-severe rash to vancomycin or daptomycin
- Suspected or confirmed MRSA pneumonia
- Known vancomycin minimum inhibitory concentration (MIC) greater than or equal to 2mg/L or daptomycin MIC greater than or equal to 1mg/L
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Australia · 12 centers
- Blacktown Hospital — Blacktown
- Concord Repatriation and General Hospital — Concord
- John Hunter Hospital — Newcastle
- Westmead Hospital — Westmead
- Royal Brisbane and Women's Hospital — Herston
- Flinders Medical Centre — Bedford Park
- Monash Health - Casey Hospital — Berwick
- Box Hill Hospital — Box Hill
- … and 4 more centers
Canada · 7 centers
- University of Alberta Hospital — Edmonton
- Fraser Health Authority (Surrey Memorial Hospital) — Surrey
- Newfoundland Health Services (Health Sciences Centre and St. Clare's Mercy Hospital) — St. John's
- Hamilton Health Sciences (Hamilton General Hospital and Juravinski Hospital) — Hamilton
- Sunnybrook Health Sciences Centre — Toronto
- Jewish General Hospital — Montreal
- McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital) — Montreal
Publications
- Zhang G, Zhang N, Xu J, Yang T, Yin H, Cai Y. Efficacy and safety of vancomycin for the treatment of Staphylococcus aureus bacteraemia: a systematic review and meta-analysis. Int J Antimicrob Agents. 2023 Oct;62(4):106946. doi: 10.1016/j.ijantimicag.2023.106946. Epub 2023 Aug 4. PMID 37543121
- Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fatkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE; S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endoc PMID 16914701
Identifiers
NCT: NCT06637332 · 2025-10666 · 466322